Real-World Effectiveness of Biologics in Patients With Severe Asthma: Analysis of the KoSAR
So-Young Park,Sun-Kyung Lee,Woo-Jung Song,Min-Hye Kim,Ga-Young Ban,Joo-Hee Kim,Byung-Keun Kim,Jae-Woo Kwon,Kyoung-Hee Sohn,Hwa Young Lee,Jae-Woo Jung,Chan-Sun Park,Sung-Yoon Kang,Min Suk Yang,Jae Hyun Lee,An-Soo Jang,So Ri Kim,Taehoon Lee,Chin Kook Rhee,Heung-Woo Park,Sang-Hoon Kim,Yoon-Seok Chang,Young-Il Koh,Byung-Jae Lee,Hae-Sim Park,Sang-Heon Kim,You Sook Cho
DOI: https://doi.org/10.4168/aair.2024.16.3.253
Abstract:Purpose: Severe asthma is associated with high morbidity and healthcare utilization; however, treatment options for these patients are limited. This study aimed to determine the therapeutic effects of biologics in clinical practice. Methods: This multicenter, retrospective cohort study included 136 patients who received biologics for at least 4 months between September 2017 and July 2022 at 25 medical centers affiliated with the Korean Severe Asthma Registry (KoSAR). The study evaluated the treatment effects, including acute exacerbation rates, maintenance of oral corticosteroid dosages, lung function, quality of life, blood eosinophil count, and fractional exhaled nitric oxide (FeNO) levels, by comparing measurements before and after 4 months of biologic treatment. Responses for each medication was evaluated based on the Global Evaluation of Treatment Effectiveness score, and any adverse reactions were summarized. Results: With the administration of biologics over the course of 4 months, there was a reduction in asthma acute exacerbations, a significant improvement in lung function, and a significant decrease in daily maintenance dose of oral steroid. Blood eosinophil counts decreased in the mepolizumab and reslizumab groups, while FeNO levels decreased only in the dupilumab group. The Asthma Control Test, Quality of Life Questionnaire for Adult Korean Asthmatics, and the EuroQol-visual analogue scale scores showed a significant improvement. Most patients (80.15%) responded to the biologic treatment. Meanwhile, non-responders often had chronic rhinosinusitis as a comorbidity, exhibited lower lung function, and required higher doses of oral steroids. No severe adverse events were reported. Conclusions: Biologics are highly effective in Korean patients with Type 2 severe asthma, significantly reducing acute exacerbation rates and doses of oral corticosteroids, while also improving lung function. Therefore, it seems beneficial to administer biologics without any restrictions to patients exhibiting Type 2 severe asthma.